The EMPAG-HF study aimed to evaluate whether early initiation of SGLT2 inhibition with empagliflozin, in combination with standard medical therapy, could enhance diuresis without exacerbating kidney injury in patients admitted with AHF within the first 12 h. Here, SLC5A2 is linked to hydrops fetalis.